Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Show more

Location: One World Trade Center, Suite 8500, New York, NY, 10007, United States | Website: https://www.mindmed.co | Industry: Biotechnology | Sector: Healthcare


Market Cap

609M

52 Wk Range

$4.70 - $10.44

Previous Close

$8.10

Open

$8.05

Volume

1,580,654

Day Range

$7.76 - $8.17

Enterprise Value

299.9M

Cash

212.4M

Avg Qtr Burn

-22.99M

Insider Ownership

0.85%

Institutional Own.

55.18%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.